Neoadjuvant Tislelizumab in Combination With Dasatinib and Quercetin in Resectable HNSCC (COIS-01)

Summary

The trial is being conducted to evaluate the efficacy and safety of Tislelizumab in combination with dasatinib and quercetin(combining immunotherapy and senolytics, COIS) in patients with head and neck squamous cell carcinoma who are about to undergo surgery.

Timeline

Start

2023-02-05

Primary completion

2024-04-05

Completion

2028-08-05

Publications

• Liu N, Wu J, Deng E, Zhong J, Wei B, Cai T, Xie Z, Duan X, Fu S, Osei-Hwedieh DO, Huang K, Zhuang P, Sha O, Chen Y, Lv X, Zhu Y, Zhang L, Lin H, Li Q, Lu P, Miao J, Yamada T, Cai L, Du H, Baca SC, Huang Q, Ferrone S, Wang X, Xu F, Fan X, Fan S. Immunotherapy and senolytics in head and neck squamous cell carcinoma: phase 2 trial results. Nat Med. 2025 Sep;31(9):3047-3061. doi: 10.1038/s41591-025-03873-7. Epub 2025 Aug 25.

Drugs

Indications